X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Schizophrenia drug Risperdal is arranged in a Cambridge, Massachusetts pharmacy Tuesday, October 17th. Johnson & Johnson said third-quarter earnings rose 8.7 percent led by sales of prescription drugs inlcuding the schizophrenia drug Risperdal. Schizophrenia drug Risperdal. Photo: Bloomberg

The $8 billion Risperdal verdict last week against Johnson & Johnson raised an increasingly common question: What convinces jurors to come back with such stratospheric awards?

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 3 articles* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

Amanda Bronstad

Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Critical Mass. She is based in Los Angeles.

More from this author

Law Firms Mentioned

 

Product LiabilityBook

An excellent comprehensive guide for the products liability practitioner ... a must for every litigator's law library. Richard J. Phelan, Past President of t...
Get More Information

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.